An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)
Alexion Pharmaceuticals, Inc.
Summary
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Description
The study will capture post-marketing safety data on patients treated with eculizumab or ravulizumab. Additionally, the study will collect information on the progression of disease in all patients.
Eligibility
- Age range
- Not specified
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female patients of any age, including minors, who have been diagnosed with aHUS * Patients with or without an identified complement pathogenic variant or anti-complement factor antibody * Able to give written informed consent. Patient or patient's parent/legal guardian must be willing and able to given written informed consent and the patient (if minor) must be willing to give written informed assent \[if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)\]. * ADAMTS13 \> 5%, if performed. Exclusion Criter…
Locations (141)
- Clinical Trial SiteAurora, Colorado
- Clinical Trial SiteWashington D.C., District of Columbia
- Clinical Trial SiteGainesville, Florida
- Clinical Trial SiteAtlanta, Georgia
- Clinical Trial SiteChicago, Illinois
- Clinical Trial SiteBoston, Massachusetts